Register Login
Register to leave comments
  • News bot Oct. 1, 2025, 8:02 p.m.

    📋 CULLINAN ONCOLOGY, INC. (CGEM) - Financial Results

    Filing Date: 2022-05-16

    Accepted: 2022-05-16 06:52:56

    Event Type: Financial Results

    Event Details:

    Cullinan Oncology Inc (CGEM) Reports Q2 2022 Financial Results Cullinan Oncology Inc (CGEM) announced its financial results for the period ending Q2 2022. Key Financial Highlights:
    • Revenue: Not disclosed
    • Net Income: (794
    • EPS: Not disclosed
    • Cash and equivalents: 410063
      • “We made excellent progress in the first quarter of 2022, substantially advancing our lead asset, CLN
      • 081, and continuing to progress our diversified pipeline,” said Nadim Ahmed, Chief Executive Officer of Cullinan Oncology. “Our March clinical and regulatory update for CLN
      • 081 further affirmed its differentiated profile, and we are looking forward to sharing an additional clinical update in an oral presentation at the upcoming ASCO meeting. We also announced a U.S. co
        • expected by mid-2023

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2022 2021 Change ($) Change (%)
    Other Income Expense Interest Income 197.00 137.00 $60.00 +43.80%
    Net Loss Attributable Common Stockholders 12.10K 32.51K $-20.41K -62.79%
    Net Loss Per Share 0.27 0.74 $-0.47 -63.51%
    Weighted Average Shares 44.43M 43.64M $788.26K +1.81%
    Loss from Operations 32.66K 34.35K $-1.69K -4.92%
    Interest Income 197.00 137.00 $60.00 +43.80%
    Net Loss 12.10K 32.51K $-20.41K -62.79%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval: Not available
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Cullinan Oncology Inc
    • CIK: 0001789972
    • Ticker Symbol: CGEM
    • Period End Date: 2022-05-16
    • Document Type: 8-K

Search

News categories